the Emergence of an effective vaccine against the coronavirus can cause problems in the stock markets, analysts at Goldman Sachs, says Bloomberg.
Investors should consider the risk that a vaccine will lead to volatility and the sale of bonds. Also, economists predict the outflow of funds of shares of technology companies in cyclical stocks. The market is underestimating the possibility of a successful vaccine trials in November, warns the Bank.
If her appearance will coincide with the change of US administration, the shares of developing countries can win, says Goldman Sachs. Analysts advise investors to invest in the options.
Earlier, the Singaporean hedge Fund APS Asset Management Pte proposed to abandon the low-yielding and safe assets in favor of cash amid the risk of a military conflict, the United States and China. Among the are low-yielding US treasuries. In June, the U.S. national debt has reached 26 trillion dollars, setting an absolute record.
